Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment

Targeted drug delivery using genetically engineered diatom biosilica

“…Simultaneously loading antibody molecules and chemotherapeutic drugs, which generally are poorly water soluble, is not trivial, as the organic solvents required to dissolve the drug molecules denature the antibody molecules. To circumvent this problem, we used a two-step strategy 20,21 . In the first step, a hydrophobic anticancer drug was incorporated into cationic lipid-based colloids (liposomes or micelles).…”

“…To achieve (a), we use a recently developed method termed live diatom silica immobilization (LiDSI) 17,18 , to incorporate GB1, an immunoglobulin G (IgG)-binding domain of protein G 19 , into the biosilica of the diatom T. pseudonana in vivo and investigate the attachment of IgG antibodies to the genetically engineered biosilica. To achieve (b), we use an established method to encapsulate hydrophobic drug molecules into cationic micelles and liposomes 20,21 , followed by investigations on their biosilica-binding properties and the release of the drug molecules. This two-step strategy is necessary, as loading of the diatom frustules with a hydrophobic drug from an organic solvent would denature the antibody.…”

“…This two-step strategy is necessary, as loading of the diatom frustules with a hydrophobic drug from an organic solvent would denature the antibody. This approach leads to multistage drug-delivery vehicles 19,20 , where drug-loaded nanoscale vehicles can be deployed once the biosilica has attached to tumour cells ( Fig. 1) 20,21 .…”

Multistage vector delivery of sulindac and silymarin for prevention of colon cancer

“…Our previous work has demonstrated the multifunctional nature of this carrier, as a variety of therapeutic agents and nanoparticles can be loaded within the pores of the silicon material. For instance, the MSV has previously been used for the delivery of drug-encapsulated micelles [18], liposomes [19][20][21][22][23][24], and polymeric nanoparticles [25][26][27][28].…”

2'-(2-bromohexadecanoyl)-paclitaxel conjugate nanoparticles for the treatment of non-small cell lung cancer in an orthotopic xenograft mouse model

“…[5][6][7][8] Due to moderate drug solubility or rapid drug release of most PX nanoformulations, lipophilic PX conjugates or derivatives have been developed to increase the stability in hydrophobic carrier systems. Previously Ali et al synthesized a series of lipophilic PX conjugates bearing 6, 8, 12, 14, or 16-carbon chains at the 2′-position.…”